Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar – West Coast
Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this 90-minute webinar is for you!
This high-impact, 90-minute educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.
The treatment of multiple myeloma has dramatically evolved in recent years with immune-based strategies resulting in a very high impact in the relapsed refractory setting. Several targets are being evaluated, but B cell maturation antigen (BCMA) has proven to result in high response rates with excellent duration of responses in a very heavily pretreated patient population. Given the plethora of different drug products in this space, including antibody-drug conjugates, T cell engagers and CAR T cells, this is a busy landscape and requires specific education around patient characteristics, treatment selection, and toxicity management to provide the best treatment options for our patients.